Commissioning Policy: Implementation of Guidance Produced by the National Institute for Health and Care Excellence

Similar documents
The Newcastle upon Tyne Hospitals NHS Foundation Trust. Implementation Policy for NICE Guidelines

Appendix 1. Policy on the Dissemination, Implementation and Monitoring of National Clinical Guidance

COMMISSIONING FOR QUALITY FRAMEWORK

NICE Charter Who we are and what we do

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health and Social Care Directorate Quality standards Process guide

MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY

POLICY ON THE IMPLEMENTATION OF NICE GUID ANCE

Document Details Clinical Audit Policy

How NICE clinical guidelines are developed

Clinical Audit Strategy 2015/ /18

Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31

SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY

Patient Safety, Quality & Risk Committee Terms of Reference

NHS ISLE OF WIGHT CLINICAL COMMISSIONING GROUP CLINICAL FUNDING AUTHORISATION POLICY

NHS. The guideline development process: an overview for stakeholders, the public and the NHS. National Institute for Health and Clinical Excellence

Regional Medicines Optimisation Committees

VELINDRE NHS TRUST. Trust Procedure PROCEDURE FOR THE IMPLEMENTATION OF NATIONAL INSTITUTE OF HEALTH & CLINICAL EXCELLENCE (NICE) GUIDANCE

Final Accreditation Report

Methods: Commissioning through Evaluation

JOB DESCRIPTION JOB DESCRIPTION

Ethical framework for priority setting and resource allocation

Methods: National Clinical Policies

Learning from Deaths Policy A Framework for Identifying, Reporting, Investigating and Learning from Deaths in Care.

NON-MEDICAL PRESCRIBING POLICY

Job Title: Head of Patient &Public Engagement and Patient Services Directorate: Corporate Affairs Department: Patient and Public Engagement

CCG Policy for Working with the Pharmaceutical Industry

NHS HARINGEY CLINICAL COMMISSIONING GROUP EMERGENCY PREPAREDNESS, RESILIENCE AND RESPONSE (EPRR) POLICY

NHS WOLVERHAMPTON CLINICAL COMMISSIONING GROUP CONSTITUTION

Guidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products

Patient Experience Strategy

Continuing Healthcare Policy

Agenda Item: REPORT TO PUBLIC BOARD MEETING 31 May 2012

HEALTHCARE INSPECTORATE WALES SAFEGUARDING AND PROTECTING CHILDREN IN WALES:

CLINICAL GOVERNANCE AND QUALITY COMMITTEE. Final - Terms of Reference - Final

Research & Development Annual Report

Vanguard Programme: Acute Care Collaboration Value Proposition

Nursing, Health Visiting and Allied Health Professional Preceptorship Policy

JOB DESCRIPTION DIRECTOR OF SCREENING. Author: Dr Quentin Sandifer, Executive Director of Public Health Services and Medical Director

NHS England (Wessex) Clinical Senate and Strategic Networks. Accountability and Governance Arrangements

REPORT TO MERTON CLINICAL COMMISSIONING GROUP GOVERNING BODY

Our Proposals for the Implementation of Urology Services in Western and Northern Trusts

GOVERNING BODY REPORT

This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.

PATIENT ACCESS POLICY (ELECTIVE CARE) UHB 033 Version No: 1 Previous Trust / LHB Ref No: Senior Manager, Performance and Compliance.

CLINICAL AND CARE GOVERNANCE STRATEGY

Framework for managing performer concerns NHS (Performers Lists) (England) Regulations 2013

WORKING WITH THE PHARMACEUTICAL INDUSTRY

Trust Board Meeting: Wednesday 13 May 2015 TB

QUALITY STRATEGY

REFERRAL TO TREATMENT ACCESS POLICY

Vision 3. The Strategy 6. Contracts 12. Governance and Reporting 12. Conclusion 14. BCCG 2020 Strategy 15

PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK

Safeguarding Children Policy Sutton CCG

Please find below the response to your recent Freedom of Information request regarding Continence Services within NHS South Sefton CCG.

COMMISSIONING SUPPORT PROGRAMME. Standard operating procedure

Safeguarding Annual Assurance Self-assessment Tool. Sheffield Health and Social Care NHS Foundation Trust

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Clinical Coding Policy

GOVERNING BODY REPORT

Wig and Hair Replacement Policy

Children Looked After Policy and Framework

MERTON CLINICAL COMMISSIONING GROUP GOVERNING BODY

h. HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST LEARNING FROM DEATHS POLICY. Broad Recommendations / Summary

NHS QIS & NICE Advice. defi nitions & status

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme

QUALITY COMMITTEE. Terms of Reference

DRAFT - NHS CHC and Complex Care Commissioning Policy.

CLINICAL GOVERNANCE STRATEGY. For West Sussex PCT

Application Pack: Applicants for Transformation Manager

MATERNITY SERVICES RISK MANAGEMENT STRATEGY

Draft National Quality Assurance Criteria for Clinical Guidelines

Looked After Children Annual Report

Collaborative Agreement for CCGs and NHS England

British Association of Dermatologists

MEMORANDUM OF UNDERSTANDING THE PROVISION OF PUBLIC HEALTH ADVICE TO NHS COMMISSIONING IN ROTHERHAM

Medicines Governance Service to Care Homes (Care Home Service)

JOB DESCRIPTION. WMAHSN Patient Safety Programme Manager

Policy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations

EXECUTIVE MEDICAL DIRECTOR JOB DESCRIPTION. Medical Education Leads Clinical Directors (professional leadership) Director of Clinical Audit

Medicines Optimisation Strategy

TITLE OF REPORT: Looked After Children Annual Report

Northumberland, Tyne and Wear NHS Foundation Trust. Board of Directors Meeting. Meeting Date: 25 October Executive Lead: Rajesh Nadkarni

Surrey Downs Clinical Commissioning Group Governing Body Part 1 Paper Acute Sustainability at Epsom & St Helier University Hospitals NHS Trust

Clinical guideline for the prevention and treatment of osteoporosis

CCG authorisation: the role of medicines management

Information Governance Management Framework

BARIATRIC SURGERY SERVICES POLICY

WORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0

Protecting the NHS investment; supporting the preceptorship of newly qualified staff. A consultation on the way forward

Supporting information for appraisal and revalidation: guidance for Occupational Medicine, April 2013

NHSLA Risk Management Standards

Implementation of the right to access services within maximum waiting times

Status: Information Discussion Assurance Approval. Claire Gorzanski, Head of Clinical Effectiveness

Tissue Viability Society. Strategy A future plan for the Tissue Viability Society (TVS) where we are going and how we will get there...

Non Medical Prescribing Policy

MORTALITY REVIEW POLICY

Learning from Deaths Framework Policy

Public health guideline Published: 11 November 2011 nice.org.uk/guidance/ph36

REPORT TO CROYDON CLINICAL COMMISSIONING GROUP GOVERNING BODY Meeting in Public. 30 October 2012

21 March NHS Providers ON THE DAY BRIEFING Page 1

Transcription:

Commissioning Policy: Implementation of Guidance Produced by the National Institute for Health and Care Excellence NHS Swindon Clinical Commissioning Group November 2015

NHS Swindon Clinical Commissioning Group (CCG) Policy Policy Ref. Policy Statement Version No. 2.0 Commissioning Policy: Implementation of guidance produced by the National Institute for Health and Care Excellence ClinG02 Version Date 02/10/2015 Review Date 11/11/2018 Author This policy supports NHS SCCG in attainment of its corporate objectives by promoting fair and consistent commissioning decision making across the CCG in relation to NICE guidance. This policy also supports implementation of the principles of the NICE Into Practice Guide: Using NICE guidance and quality standards to improve practice (2014) and bring the utilisation of QS to the fore of the implementation process for CCGs. The Health and Social Care Act (2012) declares that the Secretary of State, in discharging their duty to improve the quality of services, 'must have regard to the Quality Standards prepared by NICE'. Although these standards set out aspirational but achievable care and are not targets, the care system should also have regard to them in planning and delivering services, as part of a general duty to secure continuous improvement in quality. Tiina Korhonen, Clinical Effectiveness Manager, SCW/CSU Responsible Owner Gill May, Executive Nurse & Caldicott Guardian Approving Body Document Control Commissioning for Quality Sub-Committee Clinical Leadership Group Governing Body Reviewers & Approvals This document requires the following reviews and approvals. Revision History Version Revision Details of Changes Date 0.1 2.12.1013 Amendments to assurance flow chart to be agreed 0.2 6.12.14 Amendments to assurance process agreed, flow chart updated Author/reviewer NHS SCCG Executive Management Team (EMT) Executive Director of Commissioning Page 2 of 13

0.3 29.5.2014 Amendments to content to reflect new implementation process 0.4 26.6.2014 3.2.1. Addition of statement regarding documenting clearly the reasons if the CCG does not implement NICE guidance. 5.1 Quarterly medicines management update by exception from providers. Six monthly Public health update on implementation progress. Business cases to be submitted to contract lead. Process flow chart: addition of dissemination of NICE primary care newsletter to surgeries via Medicines Optimisation newsletter. 1.1 24.9.2015 Page 2 Update to the purpose of the policy statement as per latest national guidance. Section 4. Page 7. New NICE products added to list. Section 6. Page 10. Updated to reflect the agreed monitoring arrangements. Document transferred to new corporate template for polices. 1.2 02.10.2015 Minor formatting undertaken and revision history updated. Clinical Effectiveness Manager (CEM) Commissioning for Quality Sub-Committee Commissioning for Quality Sub-Committee Clinical Effectiveness Manager and Corporate & Information Governance/Risk Manager Acknowledgement of External Sources List any policies or procedures from external institutions that have been used to inform the writing of this policy. Title/Author/ Institution NHS England Comment / Link Links or overlaps with other key documents & policies Policy based on NHS England Commissioning Policy: Implementation and funding of NICE guidance. April 2013 Document Title Version and Issue Date Link/Document Effective Clinical Commissioning October 2013 http://www.swindonccg.nhs.uk/ Polices policies Distribution and Consultation This document has been distributed to the following people Name Date of Issue Version Page 3 of 13

Swindon Borough Council Evidence and Evaluation Lead 3.6.14 0.3 Great Western Hospital NHS Foundation Trust 8.2014 1.0 Commissioning for Quality Sub-Committee 24.9.2015 1.1 Clinical Leadership Group 11.11.2015 1.2 Governing Body 21.01.2016 1.2 Document Version Numbering Document versions numbered 0.1, 0.2, 2.4, are draft status and therefore can be changed without formal change control. Once a document has been formally approved and issued it is version numbered Issue 1.0 and subsequent releases will be consecutively numbered 2.0, 3.0, etc., following formal change control. Freedom of Information If requested, this Document may be made available to the public and persons outside the healthcare community as part of NHS Swindon Clinical Commissioning Group s commitment to transparency and compliance with the Freedom of Information Act. Accessibility This document is available in other styles, formats, sizes, languages and media in order to enable anyone who is interested in its content to have the opportunity to read and understand it. These alternatives include but are not limited to: Alternative languages and dialects Larger and smaller print options (font 8 to 18) Simplified versions including summaries and translation into symbols Audio or read versions Web based versions that can be zoomed into or shrunk on screen Braille Page 4 of 13

Table of Contents Contents 1. Introduction... 6 2. Purpose... 6 3. Scope... 6 4. Definitions... 6 5. Process / Details of Policy or Procedure... 8 6. Roles and Responsibilities... 10 7. Training... 10 8. Equality and Diversity... 11 9. Monitoring... 11 10. Review... 11 11. Dissemination... 11 12. Implementation... 11 13. References to other documents... 12 Appendix 1 NICE implementation flow chart..13 Page 5 of 13

Commissioning Policy: Implementation of Guidance Produced by the National Institute for Health and Care Excellence 1. Introduction This policy sets out NHS Swindon Clinical Commissioning Group s (CCG) approach to considering and implementing the guidance produced by the National Institute for Health and Care Excellence (NICE), as part of the CCG NICE assurance process. 2. Purpose The purpose of the guidance produced by NICE is to help the NHS provide high quality care that is consistent across England. It does this by giving the NHS evidence-based guidance on new medicines, surgical interventions, diagnostic and medical technologies, public health interventions and also by publishing clinical quality standards. The implementation of NICE guidance and quality standards is associated with high quality, best practice NHS health and social care. Nevertheless, the recommendations made by NICE need to be considered through a managed process in order to minimise any service delivery and financial risks that NICE implementation may present to commissioners and providers of NHS care. This document sets out this process. 3. Scope This policy applies to all staff and contractors employed by the CCG who are involved in the commissioning of care for patients for whom the CCG is the Responsible Commissioner for their NHS care. 4. Definitions NICE produces the following types of guidance documents: Technology Appraisal Guidance (TAs) assess the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, and also some procedures, devices and diagnostic agents. Status of TAs: TAs aim to ensure that all NHS patients have equitable access to the most clinically- and cost-effective treatments that are available, and NHS commissioners are mandated to make funding available for the implementation of TA recommendations within 3 months of the issue of guidance. The funding requirement is set out in the The NHS Constitution for England. Page 6 of 13

Clinical Guidelines (CGs) provide the NHS with advice on the management of specific health conditions, and currently are developed in association with the Royal Medical, Nursing and Midwifery Colleges. They are systematically developed statements to assist professional and patient decisions about appropriate care in specific clinical circumstances. Where there is no robust peer-reviewed evidence to underpin interventions integral to a care pathway, the Clinical Guideline Development Group will make recommendations based on professional consensus. Status of CGs: CGs relate to a whole pathway of care and consequently make a number of recommendations spanning all stages of care from diagnosis to treatment. In view of their complexity, CGs are not subject to statutory funding directions, and their implementation is at the discretion of local commissioners of NHS care. Public Health Guidelines (PHG) covers disease prevention, health improvement and health protection and seeks to influence policy and practice in the NHS and local government on issues of great importance to health and health service utilisation such as smoking, obesity, physical exercise, alcohol misuse and accident prevention. Social Care Guidelines (SCG) SCG make evidence-based recommendations on "what works" in terms of both the effectiveness and cost-effectiveness of social care interventions and services. Safe Staffing Guidelines (SSG) SSG is a new work programme for NICE to develop evidence-based guidelines on safe staffing levels in NHS care settings. Medicines Practice Guidelines (MPG) MPG provide recommendations for good practice for those individuals and organisations involved in governing, commissioning, prescribing and decision-making about medicines. The outputs have a wide range of audiences across both health and social care environments. Status of NICE Guidance (NG) on PHG, SCG, SSG and MPG: As with CGs above, implementation is at the discretion of local commissioners of NHS care. Medical Technologies Guidance and Diagnostic Technologies Guidance MTGs and DTGs help facilitate rapid and consistent access to, and use of, potentially cost saving technologies in the NHS. Status of MTGs and DTGs: Implementation is at the discretion of local commissioners of NHS care. Interventional Procedures Guidance (IPGs) recommend whether procedures are effective and safe enough for use in the NHS. IPGs do not consider cost effectiveness. Status of IPGs: IPGs are not subject to a mandatory requirement regarding funding but health care organisations should protect patients by following IPGs as outlined in the Page 7 of 13

Department of Health's 'Standards for better health' (2004). The recommendations in IPGs may be enforceable by the Care Quality Commission, and the NHS Litigation Authority takes adherence into account in risk assessing NHS Trusts. Quality standards (QSs) are concise statements, with accompanying metrics, designed to drive and measure priority quality improvements within a particular area of care. They are derived from the best available evidence collated and synthesised by NICE or, where syntheses do not exist, from other evidence sources accredited by NICE. Status of QSs: the NHS is expected to use QSs to plan and deliver services as part of a general duty to secure continuous improvement in quality. Clinical Commissioning Groups might wish to use selected indicators to monitor provider performance. 5. Process / Details of Policy or Procedure 5.1. NICE Technology Appraisals The NHS Swindon CCG will implement NICE technology appraisals in line with the Directions issued by the Secretary of State for Health. The CCG accepts that it has a legal duty to make funding available for treatments recommended in NICE Technology Appraisals within 3 months to patients whose clinical conditions come within the definitions in the appraisals, unless the Secretary of State makes an exemption. Implementation of CCG s duty to fund NICE Technology Appraisals is supported by the Innovation Health and Wealth, Accelerating Adoption and Diffusion in the NHS that requires providers of NHS care to maintain and publish formularies that include NICE TA-approved medicines. 5.2 Other NICE guidance All other NICE guidance is advisory, and will be carefully considered by NHS Swindon CCG when developing strategies, planning services and prioritising resources. The CCG reserves the right to depart from NICE guidance, if the CCG has good reason to do so. 5.2.1 Implementation of NICE Clinical Guidelines, Public Health, Social Care, Safe Staffing and Medicines Practice Guidelines (NICE Guidance) NICE s guidelines relate to whole pathways of care and can make a large number of recommendations spanning all stages of care from diagnosis to treatment. In view of their complexity, NICE guidelines are not subject to statutory funding directions, and their local implementation is therefore at the discretion of NHS Swindon CCG. NHS Swindon CCG will consider the recommendations in NICE Guidelines as part of its on-going work to improve the quality of care and health outcomes for the local population (NHS Swindon CCG NICE implementation process, Appendix 1). If the CCG cannot implement relevant NICE guidance as it is published or in full, due to commitments made in the annual commissioning plan and/or affordability (except Page 8 of 13

technology appraisals which are mandated), the CCG will document clearly the reasons for not implementing the guidance and the review plan. 5.2.2 Implementation of NICE Interventional Procedures Guidance (IPGs) The IPG programme assesses the efficacy and safety of interventional procedures, with the aim of protecting patients and helping clinicians, healthcare organisations and the NHS to introduce procedures appropriately. NICE IPGs indicate the circumstances in which an intervention might be used and provide a process as to how it might be used (which must be followed if the IPG is implemented). However, NICE IPGs do not make recommendations as to whether the intervention should be used. The use of any intervention assessed by NICE under their IPG programme is a low priority and not normally funded by NHS Swindon CCG unless: 1. The intervention has been categorised by NICE as safe and efficacious and the clinical governance arrangements have been described as Normal ; AND 2. Funding has been agreed by commissioners through the funding route detailed below. Funding route: To obtain funding, a business case must be submitted to NHS Swindon CCG in advance of the use of the intervention. This requirement applies even if the intervention is included in tariff. Regardless of equivalent cost, NHS Swindon CCG will not commission the use of interventions that are less effective or pose a greater risk to patients than standard interventions. Trusts wishing to undertake research associated with the use of IPG interventions must apply for research funds in the usual way. 5.2.3. Implementation of NICE Medical Technologies Guidance (MTGs) and Diagnostic Technologies Guidance (DTGs) NICE MTGs and DTGs review the clinical and cost impact evidence for a technology compared with currently available technologies. NICE indicates the circumstances in which a technology might be used, however, MTGs and DTGs do not make recommendations as to whether a technology should be used, and do not override clinical judgement for any individual patient. The use of any intervention assessed by NICE under their MTG and DTG programmes is a low priority and not normally funded by NHS Swindon CCG unless: 1. NICE has stated The case for adoption within the NHS as described is supported by the evidence AND Page 9 of 13

2. Funding has been agreed by commissioners through either of the funding routes detailed below. Funding route: To obtain funding, in advance of the use of a medical or diagnostic technology supported by NICE, the provider must submit a business case to NHS Swindon CCG for approval OR NHS Swindon CCG agrees to commission the technology following consideration of an evidence review. This approval process applies even if the technology is included in tariff. 6. Roles and Responsibilities CCG Governing Body has the responsibility for ensuring that there is comprehensive NICE implementation policy and process in place for the CCG. The Commissioning for Quality Sub-Committee will provide assurance to the Integrated Governance Committee and Governing Body in relation to the quality of commissioned services, including the implementation of the NICE policy and process. The Southern Central and West Commissioning Support Unit (SCWCSU) Clinical Effectiveness team will provide the CCG Commissioning for Quality Sub-Committee the appropriate support to enable it to fulfil its functions in supporting the implementation of the NICE policy and process. Provider Contract Quality Review meetings: 5. Training CCG Quality Schedule will reflect the reporting on provider progress in implementing; 1. Quality Standards; bi-annual progress reports for QSs include indication of implementation status, whether an action plan is in place, review date; and for not implemented standards, detail of any issues for commissioner support, as necessary. 2. Assurance of implementation of TAs; for all other NICE guidance; bi-annual exception reporting. 3. Issues arising from this report in the provider Contract Quality Review meeting will be brought back to the attention of the relevant CCG commissioning lead for consideration and action plan as necessary, to inform business planning discussions by identifying priority areas for improvement. 4. NICE implementation process and progress is discussed as part of the review meeting as per contractual arrangements. No specific training is necessary to support this policy. Page 10 of 13

6. Equality and Diversity No significant issues identified. 7. Monitoring The Swindon CCG Commissioning for Quality Sub-Committee will oversee the implementation of the NICE policy. The Commissioning for Quality Sub-Committee will: Review six monthly update by the medicines management team on exceptions arising from NICE Technology Appraisals by provider organisations. Review six monthly update by the Public Health team on any implementation issues or exceptions relating to Public Health Guidance. Assess business cases submitted to the Commissioning for Quality Committee by the provider organisations in regard to implementing new procedures as per IPG, MTG and DTG recommendations. Business cases should be submitted to the CCG Commissioning Contract Lead, for consideration by the Commissioning for Quality Sub Committee. Actions will be communicated back to provider via the Contract Lead. 8. Review This policy will be review every three years or sooner if relevant new national directive or guidance is published. 9. Dissemination SCWCSU team is, in conjunction with the CCG s Commissioning Contract Lead and Communications and Engagement Team, responsible for the dissemination of the approved policy to all CCG staff including its availability via the CCG s intranet. 10. Implementation Senior managers, managers and staff are responsible for implementing this policy. Page 11 of 13

11. References to other documents 1. Department of Health Directions to Primary Care Trusts and NHS trusts in England concerning Arrangements for the Funding of Technology Appraisal Guidance from the National Institute for Clinical Excellence. http://www.info.doh.gov.uk/doh/finman.nsf/0/6dbfb0cd58b8139180256b2100615694?o pendocument 2. Innovation Health and Wealth, Accelerating Adoption and Diffusion in the NHS (2012) https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213204/c reating-change-ihw-one-year-on-final.pdf 3. Department of Health (2013) The NHS Constitution for England http://www.nhs.uk/choiceinthenhs/rightsandpledges/nhsconstitution/pages/overview.aspx 4. NHS England (2013) Commissioning Policy: Implementation and funding of NICE guidance. http://www.england.nhs.uk/wp-content/uploads/2013/04/cp-05.pdf 5. NICE - Benefits of Implementing NICE. http://www.nice.org.uk/about/what-we-do/into-practice/benefits-of- NICE-guidance implementing- 6. The National Prescribing Centre (2009) Supporting rational local decision-making about medicines (and treatments) http://www.npc.co.uk/local_decision_making/resources/handbook_complete.pdf Page 12 of 13